While #dupilumab can be used for #EGPA, be careful about using it in pts with high eosinophilia; don't taper steroids too rapidly if you use this drug. - Dr P Seo @rheumnow #RNL2024 https://t.co/YKQdtvCS0M

Consider using IV Benralizumab (also an IL5 inhibitor) for #EGPA in pts where insurance won't approve SQ mepolizumab - Dr. P Seo #RNL2024 @rheumnow https://t.co/VFE76Uzb2S

EGPA - Peanut butter and Jelly @philseo Respiratory symptoms and systemic disease Respiratory: non-systemic (inhalers, steroids, irrigation) IL-5 inhibs Non-respiratory: eosinophilic (myocarditis, urticaria, EE), vasculitis (MM, GN, DAH, purpura, arthralgias) #RNL2024 @RheumNow https://t.co/KTlvZ1cnfH

"EGPA is a lot like peanut butter and jelly, two separate things showing up at the same time (in terms of respiratory and systemic manifestations.)" Dr. @philseo at #RNL2024 @RheumNow https://t.co/l0WgG1caN0

“Patients with EGPA are like peanut butter and jelly … 2 different manifestations: respiratory manifestations and systemic manifestations” - Dr. P Seo with lunch on his mind. #RNL2024 @rheumnow https://t.co/y7SLEG9qRt

The great unknown with tocilizumab in GCA, do you stop, how do you stop, etc. @philseo approach. I'm not as brave! Usually park at every other week dosing @RheumNow #RNL2024 https://t.co/y7mg57mWND

Do you have GCA patients on low dose prednisone? Feel reassured. Dr. @philseo provides data showing that low dose prednisone may be helpful in remission maintenance. #RNL2024 @RheumNow https://t.co/oyOsczfkfv

Interesting nuance from @philseo re tocilizumab in GCA. For new onset disease, it may be appropriate to use every other week tocilizumab @RheumNow #RNL2024 https://t.co/moCvpQSkq0

Amaurosis fugax is not the only vision symptoms to assess in patients with #GCA. Blue vision, double vision (if patients have to look at you in a side gaze prevent double vision) may also be present - Dr. P Seo @rheumnow #RNL2024 https://t.co/AhQnOJF7fa

#RNL2024 @RheumNow @philseo: I now give Tociliizumab for nearly all patients with GCA GiACTA shows we weren't doing well enough with steroid monotherapy GiACTA shows dosing frequency does not make a big difference in new diagnosis, but makes a difference in relapsing disease https://t.co/JBgUQtZSAr